ATRA: Atara Biotherapeutics, Inc. Price to Sales
Atara Biotherapeutics maintains a stable drug production pipeline through its own manufacturing facility in California, although fierce competition from biotech behemoths creates significant risks. The company's price/sales multiple reveals speculative valuation distortions, with the current parameter standing at 20.30. The premium cost of therapy in the EU provides pricing power, though a narrow patient base limits the overall monetization of the business.
Metric breakdowns and analytics for Atara Biotherapeutics (ATRA)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
Total Debt to Capital Atara Biotherapeutics|ATRA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital atarabio.com|ATRA - Company Aggregate Debts|Debts to Book Capitalization Atara Biotherapeutics Inc|ATRA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Atara Biotherapeutics|Quick Liquidity atarabio.com
- company profitability and valuation multiples indicators:
ATRA - Net Profit|Company Profit Forecast Atara Biotherapeutics|ATRA - Price to Earnings Ratio|Projected Price to Earnings Ratio atarabio.com|ATRA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Atara Biotherapeutics Inc|ATRA - Operating profit EBITDA|Earnings per share for the trailing year Atara Biotherapeutics|ATRA - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months atarabio.com|ATRA - Earnings per share growth in current year|Expected earnings per share trend next year Atara Biotherapeutics
- sales revenue and business income indicators:
General company analysis:ATRA Atara Biotherapeutics, Inc.
The P/S multiple is sensitive to revenue dynamics, reflecting the market value of the business relative to its sales volume. This ratio allows for an assessment of the company's capitalization fairness by excluding the impact of temporary losses. For Atara Biotherapeutics (ATRA), this calculation confirms the value of innovations in allogeneic immunotherapy and market confidence in breakthrough drugs. By analyzing the P/S chart, an investor can promptly identify price anomalies and asset overvaluation risks.
Who Atara Biotherapeutics competes with
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT (Immunovant, Inc.) - Market Cap to Revenue|KNSA: Market Cap to Sales Volume|GRFS (Grifols) - P/S Multiple|P/S Multiple Adaptive Biotech|Price-to-Revenue Ratio Celldex (CLDX)|AUPH (Aurinia Corp) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCRX (BioCryst)|P/S Multiple veratx.com VERA|DNTH: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PHVS (Pharvaris NV)|ABCL: P/S Multiple|TRML (Tourmaline) - Price-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Cap to Sales Volume IMNM (Immunome Bio)|Gossamer Bio, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio KALV (kalvista.com)|SEPN: P/S Multiple|Price to Sales Pieris Pharma (PVLA)|Price-to-Revenue Ratio Savara Corp|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|Price-to-Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Price-to-Sales Ratio|Aerovate - P/S Multiple|Price to Sales Aclaris Therapeutics, Inc|KYTX (Kyverna Therapeutics) - Market Cap to Revenue|tizianalifesciences.com (TLSA) - P/S Multiple|Market Cap to Revenue CABA|VTYX (Ventyx Biosciences Inc.) - Market Cap to Sales Volume|P/S Multiple THTX|Price-to-Revenue Coefficient Avalo Therapeutics Inc|P/S Multiple ELDN (Eledon Pharmaceuticals)|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Zura Bio Ltd ZURA|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Market Cap to Revenue IMA|STTK (Shattuck Therapeutics) - Market Cap to Sales Volume|Price-to-Revenue Ratio Equillium, Inc. (EQ)|CNTB (connectbiopharm.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple IMUX (Immunic)|P/S Multiple InflaRx NV IFRX|XFOR - Price-to-Revenue Ratio|Price-to-Sales Ratio ACET|CELU: P/S Multiple|INmune Bio Inc - Market Capitalization-to-Revenue Ratio|BRNS (Barinthus Bio) - P/S Multiple|P/S Multiple Kezar Life Sciences Inc|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|AKTX (akaritx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Enlivex Therapeutics Ltd. ENLV|QTTB - Market Cap to Revenue|GeoVax Labs Inc - P/S Multiple|EDSA - P/S Multiple|IBIO (iBio, Inc.) - Market Cap to Revenue|Carisma Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Bolt Bio (BOLT) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio HCW Biologics Inc. (HCWB)|Market Cap to Revenue aptevotherapeutics.com APVO|Price-to-Revenue Ratio AIM ImmunoTech Inc. AIM|ADTX - Market Cap to Revenue|GRI: Market Cap to Revenue|XRTX - P/S Multiple|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Price to Sales scinai.com SCNI|P/S Multiple CALI|P/S Multiple affimed.com (AFMD)|Allakos - Market Cap to Revenue|Market Cap to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGM Bio - P/S Multiple|ITOS - P/S Multiple|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
